Zevenbergen Capital Investments LLC Increases Stock Position in TransMedics Group, Inc. $TMDX

Zevenbergen Capital Investments LLC increased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 112.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 258,523 shares of the company’s stock after buying an additional 136,995 shares during the period. Zevenbergen Capital Investments LLC owned about 0.76% of TransMedics Group worth $29,006,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Opal Wealth Advisors LLC acquired a new stake in shares of TransMedics Group during the second quarter valued at about $26,000. Smartleaf Asset Management LLC increased its holdings in TransMedics Group by 44.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock worth $30,000 after purchasing an additional 135 shares during the last quarter. Quarry LP raised its position in shares of TransMedics Group by 88.5% in the 1st quarter. Quarry LP now owns 592 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares in the last quarter. Sound Income Strategies LLC purchased a new position in shares of TransMedics Group during the 2nd quarter valued at approximately $48,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of TransMedics Group during the second quarter worth approximately $48,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Buying and Selling

In other news, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40. Following the completion of the transaction, the chief financial officer owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director David Weill sold 5,000 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the transaction, the director owned 12,134 shares of the company’s stock, valued at $1,682,257.76. This represents a 29.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 13,062 shares of company stock worth $1,797,634. 7.00% of the stock is owned by company insiders.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $127.67 on Friday. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $156.00. The firm has a 50-day simple moving average of $127.74 and a 200 day simple moving average of $123.00. The company has a market cap of $4.36 billion, a PE ratio of 51.69 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The firm had revenue of $143.82 million for the quarter, compared to analysts’ expectations of $145.33 million. During the same quarter last year, the company posted $0.12 earnings per share. TransMedics Group’s revenue was up 32.2% on a year-over-year basis. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Piper Sandler cut their price target on shares of TransMedics Group from $145.00 to $140.00 and set an “overweight” rating on the stock in a report on Thursday, October 30th. Zacks Research lowered shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Evercore ISI started coverage on shares of TransMedics Group in a research report on Tuesday, September 16th. They set an “outperform” rating and a $155.00 price target on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Finally, Wall Street Zen cut TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus target price of $144.25.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.